Connecting Global Innovation to Canadian Healthcare.
English
Français
About
Products
Programs
Contact
Compassionate Care Program Application
Section A: Healthcare Professional Recommender Details
To be completed by the individual requesting compassionate access on behalf of a patient.
Name
(Required)
First
Last
Title/Position
(Required)
Profession/Designation
(Required)
Qualifications
(Required)
Institution/Organization
(Required)
Department
(Required)
Institution Address
(Required)
Street Address
Address Line 2
City
State / Province / Region
ZIP / Postal Code
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos Islands
Colombia
Comoros
Congo
Congo, Democratic Republic of the
Cook Islands
Costa Rica
Croatia
Cuba
Curaçao
Cyprus
Czechia
Côte d'Ivoire
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Macedonia
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestine, State of
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Romania
Russian Federation
Rwanda
Réunion
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Sweden
Switzerland
Syria Arab Republic
Taiwan
Tajikistan
Tanzania, the United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkmenistan
Turks and Caicos Islands
Tuvalu
Türkiye
US Minor Outlying Islands
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
Åland Islands
Country
Phone
(Required)
Email
(Required)
Section B: Patient Information
Basic details to support request. Sensitive personal or medical details are not required.
Patient Name
(Required)
First
Last
Name of Recommending Healthcare Professional or Institution
(Required)
Requested GMP Medication
(Required)
Select Medication
AZITHROMYCIN FOR INJECTION, 500 mg
BORTEZOMIB FOR INJECTION, 3.5 mg
CLADRIBINE INJECTION USP, 1 mg / mL, 10 mL
DAUNORUBICIN INJECTABLE SOLUTION, 20 mg / 4 mL
DAUNORUBICIN INJECTABLE SOLUTION, 50 mg / 10 mL
FLUOROURACIL INJECTION, EP, 50 mg / mL, 1 g / 20 mL
FLUOROURACIL INJECTION, EP, 50 mg / mL, 250 mg / 5 mL
FLUOROURACIL INJECTION, EP, 50 mg / mL, 5 g / 100 mL
FLUOROURACIL INJECTION, EP, 50 mg / mL, 500 mg / 10 mL
GEMCITABINE FOR INJECTION, 200 mg
GEMCITABINE FOR INJECTION,1 g
IRINOTECAN HYDROCHLORIDE INJECTION, 20 mg / mL, 15 mL
IRINOTECAN HYDROCHLORIDE INJECTION, 20 mg / mL, 2 mL
IRINOTECAN HYDROCHLORIDE INJECTION, 20 mg / mL, 25 mL
IRINOTECAN HYDROCHLORIDE INJECTION, 20 mg / mL, 5 mL
LEUCOVORIN CALCIUM INJECTION, 1000 mg / 100 mL
LEUCOVORIN CALCIUM INJECTION, 200 mg / 20 mL
LEUCOVORIN CALCIUM INJECTION, 50 mg / 5 mL
MED-ANASTROXOLE, 1 mg
MED-BICALUTAMIDE, 50 mg
MED-BICALUTAMIDE, 50 mg
MED-BICALUTAMIDE, 50 mg
MED-BRIMONIDINE, 0.2 % w/v, 10 mL
MED-BRIMONIDINE, 0.2 % w/v, 5 mL
MED-CLINDAMYCIN, 150 mg
MED-CLINDAMYCIN, 300 mg
MED-CYPROTERONE, 50 mg
MED-CYPROTERONE, 50 mg
MED-DORZOLAMIDE-TIMOLOL, 20 mg / mL & 5 mg / mL – 10 mL
MED-DORZOLAMIDE, 20 mg / mL – 5 mL
MED-DUTASTERIDE, 0.5 mg
MED-DUTASTERIDE, 0.5 mg
MED-EXEMESTANE, 25 mg
MED-LATANOPROST OPHTHALMIC SOLUTION, 2.5 mL
MED-LATANOPROST-TIMOLOL, 2.5 mL
MED-LETROZOLE, 2.5 mg
MED-MOXIFLOXACIN, 400 mg
MED-MOXIFLOXACIN, 400 mg
MED-OLMESARTAN, 20 mg
MED-OLMESARTAN, 20 mg
MED-OLMESARTAN, 40 mg
MED-OLMESARTAN, 40 mg
MED-OLOPATADINE, 0.1 % w/v, 5 mL
MED-RIVASTIGMINE, 1.5 mg
MED-RIVASTIGMINE, 1.5 mg
MED-RIVASTIGMINE, 3 mg
MED-RIVASTIGMINE, 3 mg
MED-RIVASTIGMINE, 4.5 mg
MED-RIVASTIGMINE, 4.5 mg
MED-RIVASTIGMINE, 6 mg
MED-RIVASTIGMINE, 6 mg
MED-ROSUVASTATIN, 10 mg
MED-ROSUVASTATIN, 10 mg
MED-ROSUVASTATIN, 10 mg
MED-ROSUVASTATIN, 20 mg
MED-ROSUVASTATIN, 20 mg
MED-ROSUVASTATIN, 20 mg
MED-ROSUVASTATIN, 40 mg
MED-ROSUVASTATIN, 40 mg
MED-ROSUVASTATIN, 40 mg
MED-ROSUVASTATIN, 5 mg
MED-ROSUVASTATIN, 5 mg
MED-ROSUVASTATIN, 5 mg
MED-VORICONAZOLE, 200 mg
MED-VORICONAZOLE, 200 mg
NOREPINEPHRINE BITARTRATE INJECTION USP, 10 x 4 mL ampoules
OCTREOTIDE ACETATE INJECTION, 100 mcg / mL – 1 mL – 5 ampoules
OCTREOTIDE ACETATE INJECTION, 50 mcg / mL – 1 mL – 5 ampoules
OCTREOTIDE ACETATE INJECTION, 500 mcg / mL – 1 mL – 5 ampoules
OXALIPLATIN INJECTION AQUEOUS SOLUTION, 100 mg / 20 mL
OXALIPLATIN INJECTION AQUEOUS SOLUTION, 5 mg / mL
OXALIPLATIN INJECTION AQUEOUS SOLUTION, 50 mg / 10 mL
PANTOPRAZOLE SODIUM FOR INJECTION, 40 mg / vial, powder for solution
PANTOPRAZOLE SODIUM FOR INJECTION, 40 mg / vial, powder for solution
PANTOPRAZOLE SODIUM FOR INJECTION, 40 mg / vial, powder for solution
SUGAMMADEX INJECTION, 100 mg / mL – 2 mL
SUGAMMADEX INJECTION, 100 mg / mL – 5 mL
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 1000 mg
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 1000 mg
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 1000 mg
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 1000 mg
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 500 mg
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 500 mg
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 500 mg
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 500 mg
VINORELBINE FOR INJECTION, 10 mg / mL
VINORELBINE FOR INJECTION, 10 mg / mL
ZOLEDRONIC ACID FOR INJECTION, 4 mg / 5 mL
Does the patient currently receive coverage for the requested medication?
(Required)
Full Coverage
Partial Coverage
No Coverage
Estimated out-of-pocket cost per month for patient:
(Required)
Section C: Patient Situation Requiring Support
Please describe the circumstances that justify compassionate access to medication.
Patient Circumstances
(Required)
Section D: Supporting Healthcare Provider
Is this information the same from Section A?
Yes, same information as Section A
Name
(Required)
First
Last
Title/Position
(Required)
Profession/Designation
(Required)
Qualifications
(Required)
Institution/Organization
(Required)
Department
(Required)
Institution Address
(Required)
Street Address
Address Line 2
City
State / Province / Region
ZIP / Postal Code
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos Islands
Colombia
Comoros
Congo
Congo, Democratic Republic of the
Cook Islands
Costa Rica
Croatia
Cuba
Curaçao
Cyprus
Czechia
Côte d'Ivoire
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Macedonia
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestine, State of
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Romania
Russian Federation
Rwanda
Réunion
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Sweden
Switzerland
Syria Arab Republic
Taiwan
Tajikistan
Tanzania, the United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkmenistan
Turks and Caicos Islands
Tuvalu
Türkiye
US Minor Outlying Islands
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
Åland Islands
Country
Phone
(Required)
Email
(Required)
Section E: Healthcare Provider Signature and Submission Information
Confirmation
(Required)
The information in this form is accurate to the best of my knowledge.
I confirm that the information provided in this application is accurate and truthful to the best of my knowledge. I am recommending compassionate access to medication in good faith, based on the patient’s current situation and medical needs.
Signature
(Required)
Patient Basic Contact Information
Phone
(Required)
Email
(Required)